ProShares UltraShort NASDAQ Biotechnology
10 hedge funds and large institutions have $3.17M invested in ProShares UltraShort NASDAQ Biotechnology in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 3 closing their positions.
115% more capital invested
Capital invested by funds: $1.47M → $3.17M (+$1.7M)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
11% more funds holding
Funds holding: 9 → 10 (+1)
8.69% more ownership
Funds ownership: 6.95% → 15.63% (+8.7%)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$990K |
| 2 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$959K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$238K |
| 4 |
IMC Chicago
Chicago,
Illinois
|
+$39.4K |
| 5 |
CG
Cutler Group
San Francisco,
California
|
+$2.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$351K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$98.3K |
| 3 |
SFS
Sowell Financial Services
North Little Rock,
Arkansas
|
-$54K |
| 4 |
WP
WealthSource Partners
San Luis Obispo,
California
|
-$42K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$21K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $1.06M | +$990K | +23,559 | New |
|
|
OMC
2
Old Mission Capital
Chicago,
Illinois
| $1.03M | +$959K | +22,811 | New |
|
|
WP
3
WealthSource Partners
San Luis Obispo,
California
| $362K | -$42K | -1,000 | -11% |
|
|
4
IMC Chicago
Chicago,
Illinois
| $304K | +$39.4K | +938 | +16% |
|
|
5
Citadel Advisors
Miami,
Florida
| $256K | +$238K | +5,671 | New |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $153K | -$351K | -8,342 | -71% |
|
7
Morgan Stanley
New York
| $2K | -$14.5K | -345 | -88% |
|
8
Citigroup
New York
| $2K | – | – | – |
|
|
CG
9
Cutler Group
San Francisco,
California
| $2K | +$2.1K | +50 | New |
|
|
10
UBS Group
Zurich,
Switzerland
| – | -$98.3K | -2,340 | -100% |
|
|
SFS
11
Sowell Financial Services
North Little Rock,
Arkansas
| – | -$54K | -1,143 | Closed |
|
|
12
Simplex Trading
Chicago,
Illinois
| – | -$21K | -458 | Closed |
|
13
Osaic Holdings
Scottsdale,
Arizona
| – | -$15K | -313 | Closed |
|
BIS Hedge Fund Activity: Q1 2021 in Review
10 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q1 2021, worth a combined $3.17M — up 115% from $1.47M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BIS positions and 3 closed out — a net gain of 1 holder — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $990K. The largest seller was Tower Research Capital (TRC), cutting an estimated $351K.
- 10 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q1 2021, up from 9 in Q4 2020.
- Funds reported $3.17M of ProShares UltraShort NASDAQ Biotechnology stock for Q1 2021, up 115% quarter-over-quarter.
- 4 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q1 2021 and 3 closed out, a net change of +1 holder.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q1 2021 was Susquehanna International Group, an estimated $990K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q1 2021 was Tower Research Capital (TRC), an estimated $351K sold.
Based on aggregated 13F filings for Q1 2021.